TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04763187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: Tooth extraction and alveolus regeneration with autologous blood concentrate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth extraction and alveolus regeneration with autologous blood concentrate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: Tooth extraction and alveolus regeneration with autologous blood concentrate.
Study: NCT02940782

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc single file system
Description: A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One Shape single file system
Description: A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland
Description: It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland
Description: It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
Study: NCT01947491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Spray
Study: NCT00724009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
Study: NCT03609476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature saline instillation
Description: Saline is used as room temperature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warmed saline instillation
Description: Saline is warmed to 37Celcius prior to instillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No saline instillation
Description: No saline is used prior to catheter removal
Study: NCT04187482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All participants with DM1 will undergo a 12-week aerobic exercise training intervention on a cycle ergometer
Study: NCT00667654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Description: Testing a range of dosing configurations to optimize patient tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Description: Testing a range of dosing configurations to optimize patient tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Description: Testing a range of dosing configurations to optimize patient tolerability
Study: NCT03013556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A, TDF
Description: TDF for 96 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B:TDF then TDF and Peginterferon alfa-2a
Description: Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C:TDF and Peginterferon alfa-2a then TDF
Description: Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
Study: NCT00667654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Description: Testing a range of dosing configurations to optimize patient tolerability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Description: Testing a range of dosing configurations to optimize patient tolerability
Study: NCT03374202

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VRC-HIVAAV070-00-GT (AAV8-VRC07)
Description: AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VRC-HIVAAV070-00-GT (AAV8-VRC07)
Description: AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VRC-HIVAAV070-00-GT (AAV8-VRC07)
Description: AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07
Study: NCT04386499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: mixture of trans-resveratrol 150 mg (REVIFAST), folic acid 400 mcg, vitamin D, vitamin B12 and vitamin B6

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: 400 mcg of folic acid
Study: NCT01635764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study: NCT04063787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fist Assist
Description: The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12.
Study: NCT02124954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-8995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study: NCT02266875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard saline
Study: NCT04072107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
Study: NCT00204867

Intervention type: OTHER
Intervention: CTC surveillance
Description: In vivo CTC surveillance of 6-9 mm polyp
Study: NCT04494724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: Infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study: NCT01404637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4mg
Description: Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.2mg
Description: tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
Study: NCT01869465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-treatment snack
Description: The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education arm
Description: In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
Study: NCT02673359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Description: Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
Study: NCT00130091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: 2 mcg clonidine added to local anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clonidine
Description: 2 mcg clonidine added to local anesthetic
Study: NCT04417309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
Study: NCT01805544

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
Study: NCT04417309

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at \~50% of MHR) for 30 minutes.
Study: NCT02630186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
Study: NCT01484522

Intervention type: BIOLOGICAL
Intervention: FluMist
Description: Administered at the manufacture's recommended dose

Intervention type: BIOLOGICAL
Intervention: Fluvirin
Description: Vaccine administered at the manufacturer's recommended dose.

Intervention type: BIOLOGICAL
Intervention: Fluzone
Description: Vaccine administered at manufacturer's recommended dose
Study: NCT03845504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: Stimulation will be administered using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
Study: NCT00074789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Interpersonal Therapy
Description: Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control/usual care
Description: Participants will receive the usual care for depression.
Study: NCT01013636

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: * Anaplasma diagnosis test : serology and PCR~* If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days
Study: NCT01531244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dactinomycin
Description: Given via ILI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given via ILI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditionally replicative adenovirus 3/5-delta
Description: Given via ILI
Study: NCT03096691

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cervical pessary
Description: Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
Study: NCT02671929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic feedback
Description: Therapeutic feedback on the written information sent to the online therapist
Study: NCT00792350

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
Study: NCT00559533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045337
Description: Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
Study: NCT01380509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Capsules, single-dose, fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Capsules, single-dose, fasting
Study: NCT02461225

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia® FX-635™
Description: The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes that are applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light. It is applied for 15 minutes to each foot. The diodes are positioned around the foot such that each of the 3 laser lights is positioned between 3 and 4 inches away from, but directed toward: a) the top of the foot (dorsal aspect); b) the bottom of the foot (plantar aspect); and c) the posterior tibial nerve within the tarsal tunnel. The laser diodes laze each of these 3 areas for 15 minutes simultaneously. Each subject receives 12 total procedure administrations with the Erchonia® FX-635™ across the consecutive 6-week procedure administration phase, 2 procedure administrations per week, each procedure administration approximately evenly spaced.
Study: NCT03797833

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anaesthesia
Description: Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
Study: NCT04368286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Pulmonary rehabilitation (respiratory rehabilitation) is a comprehensive intervention based on a comprehensive patient assessment, targeted to the treatment of patients, including but not limited to exercise training, education and behavior change, aimed at improving the physical and mental health of patients with chronic respiratory diseases and promoting long-term adherence to health-enhancing behaviors.
Study: NCT03014323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Galantamine 4 mg twice a day for 4 weeks
Study: NCT04535687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib
Study: NCT00067743

Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
Study: NCT02630186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: A human IgG1 monoclonal antibody administered intravenously (IV)
Study: NCT04393402

Intervention type: PROCEDURE
Intervention: lung ultrasound (LUS)
Description: Patients with Covid-19 Disease and admitted in critical care unit will be performed a LUS
Study: NCT03492853

Intervention type: GENETIC
Intervention: DNA extraction and sequencing
Description: DNA extraction from peripheral blood and KASP sequencing

Intervention type: GENETIC
Intervention: DNA extraction and sequencing
Description: DNA extraction from peripheral blood and KASP sequencing
Study: NCT05087407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decomprssion and drainage seton
Description: Incision the internal sphincter over the fistula tract in intersphinteric space to achieve decompression then drainage seton will be put around external sphincter.
Study: NCT02297256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BMAC & Allograft
Description: Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Bone Graft
Description: Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
Study: NCT02286687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT03014323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: Galantamine 4 mg twice a day for 4 weeks
Study: NCT00600587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant erlotinib therapy
Description: 150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant gemcitabine/carboplatin therapy
Description: 3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
Study: NCT02192398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guanfacine
Description: Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized into 1 of the following 3 treatment groups:~1. guanfacine (2mg)~2. guanfacine (1mg)~3. placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo).
Study: NCT03014323

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Galantamine
Description: Galantamine 4 mg twice a day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1 capsule twice a day for 4 weeks
Study: NCT04940637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib and dostarlimab
Description: niraparib 300 mg/die and dostarlimab 500 mg day 1 Q3 weeks for the first 4 cycles followed by 1000 mg day 1 Q6 weeks
Study: NCT01526473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX901
Description: Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
Study: NCT01469078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer®
Description: Single Bolus Injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer®
Description: Single Bolus Injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monofer®
Description: Single Bolus Injections
Study: NCT00905671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiScan Coronary Imaging Catheter
Description: Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiScan Coronary Imaging Catheter
Description: Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
Study: NCT00157924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin (+) ezetimibe
Description: simvastatin (+) ezetimibe 10/20mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 10mg
Study: NCT03014323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1 capsule twice a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 capsule twice a day for 4 weeks
Study: NCT01570686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 300 mg once daily
Study: NCT04979351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal massage will be applied twice a day.